One protein identified and confirmed as increased in sapatinib-treated tumors was HO-1 (Fig. 2c; median [CI]: non-tumor: vehicle: 23.06% [13.76–32.12]; sapatinib: 27.14% [21.99–46.82]; NS; tumor: vehicle: 14.31% [8.882–26.17]; sapatinib: 50.61% [23.81–73.39]; p < 0.01). The gene discussed is HMOX1; the disease is neoplasm.